Home Biotechnology Samsung Bioepis Co., Ltd.
S

Samsung Bioepis Co., Ltd.

Profile managed by Bizz Id
South Korea 2012

Description

South Korean biopharmaceutical company founded in 2012 and focused on developing biosimilar medicines. It has approved biosimilars in immunology, oncology, ophthalmology and haematology, marketed directly and through partners, and is developing further biosimilar candidates and its own novel biologics, including antibody-drug conjugates.

Products

21 products
Adalimumab

SB5. Brand: ADALLOCE. Biosimilar of Humira. Also marketed as IMRALDI by Biogen and HADLIMA by Organon.

Aprobado EC; Aprobado HC (Canadá); Aprobado MFDS; Aprobado TGA; Aprobado FDA; Aprobado Swissmedic; Aprobado TFDA; Aprobado SFDA; Aprobado MoH (Israel); Aprobado ANVISA; Aprobado MHRA; Aprobado MOPH (Catar); Aprobado MoH (Ucrania); Aprobado KDFC (Kuwait); Aprobado Medsafe

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Adalimumab: see suppliers →

Aflibercept

SB15. Brand: AFILIVU. Biosimilar of Eylea. Also marketed as OPUVIZ by Biogen. Approved in the EU and UK; launch only after expiry of relevant SPCs.

Aprobado MFDS; Aprobado FDA; Aprobado MHLW (Japón); Aprobado EC; Aprobado HC (Canadá); Aprobado MHRA; Aprobado TGA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Aflibercept: see suppliers →

Benralizumab

SB41. Biosimilar candidate of Fasenra. Immunology. Phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Benralizumab: see suppliers →

Bevacizumab

SB8. Brand: ONBEVZI. Biosimilar of Avastin. Also marketed as AYBINTIO by Organon.

Aprobado EC; Aprobado MFDS; Aprobado HC (Canadá); Aprobado TFDA; Aprobado TGA; Aprobado MHRA; Aprobado ANVISA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Bevacizumab: see suppliers →

Canakinumab

SB44. Biosimilar candidate of Ilaris. Immunology. Phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Canakinumab: see suppliers →

Denosumab

SB16. Brand: OBODENCE, XBRYK, OSPOMYV. Biosimilar of Prolia and Xgeva.

Aprobado FDA; Aprobado EC; Aprobado MFDS; Aprobado MHRA; Aprobado Swissmedic; Aprobado TGA; Aprobado HC (Canadá); Aprobado ANVISA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Denosumab: see suppliers →

Dupilumab

SB33. Biosimilar candidate of Dupixent. Immunology. Phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Dupilumab: see suppliers →

Eculizumab

SB12. Brand: EPYSQLI. Biosimilar of Soliris.

Aprobado EC; Aprobado MFDS; Aprobado MHRA; Aprobado FDA; Aprobado ANVISA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Eculizumab: see suppliers →

Etanercept

SB4. Brand: ETOLOCE, ETICOVO. Biosimilar of Enbrel. Also marketed as BENEPALI by Biogen and BRENZYS by Organon.

Aprobado EC; Aprobado MFDS; Aprobado HC (Canadá); Aprobado TGA; Aprobado MoH (Israel); Aprobado ANVISA; Aprobado Swissmedic; Aprobado Medsafe; Aprobado FDA; Aprobado TFDA; Aprobado MOPH (Catar); Aprobado MHRA; Aprobado MOHAP (EAU); Aprobado MoH (Ucrania); Aprobado KDFC (Kuwait)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Etanercept: see suppliers →

Guselkumab

SB34. Biosimilar candidate of Tremfya. Immunology. Phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Guselkumab: see suppliers →

Infliximab

SB2. Brand: REMALOCE. Biosimilar of Remicade. Also marketed as FLIXABI by Biogen and RENFLEXIS by Organon.

Aprobado EC; Aprobado FDA; Aprobado MFDS; Aprobado HC (Canadá); Aprobado TGA; Aprobado ANVISA; Aprobado Medsafe; Aprobado MOHAP (EAU); Aprobado SFDA; Aprobado KDFC (Kuwait); Aprobado MHRA; Aprobado TFDA; Aprobado MOPH (Catar); Aprobado Swissmedic; Aprobado MoH (Ucrania)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Infliximab: see suppliers →

Ixekizumab

SB35. Biosimilar candidate of Taltz. Immunology. Phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ixekizumab: see suppliers →

Ocrelizumab

SB37. Biosimilar candidate of Ocrevus. Neurology. Phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ocrelizumab: see suppliers →

Pembrolizumab

SB27. Biosimilar candidate of Keytruda. Oncology. Phase 3 (site links phase I and phase III trials).

Under development

Finished product (FDF)

Verified on 2026-10-21

Pembrolizumab: see suppliers →

Ranibizumab

SB11. Brand: AMELIVU. Biosimilar of Lucentis. Also marketed as BYOOVIZ by Biogen. In the US, BYOOVIZ (ranibizumab-nuna) is interchangeable with Lucentis.

Aprobado FDA; Aprobado HC (Canadá); Aprobado EC; Aprobado MFDS; Aprobado Swissmedic; Aprobado TGA; Aprobado Medsafe; Aprobado MHRA; Aprobado ANVISA; Aprobado TFDA; Aprobado MoH; Aprobado SFDA; Aprobado MOHAP (EAU)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ranibizumab: see suppliers →

SBE303 (Nectin-4 ADC)

SBE303. Novel biologic (Nectin-4 ADC). Oncology. Phase 1 (site links phase I trial).

Under development

Finished product (FDF)

Verified on 2026-10-21

SBE313 (EGFR-HER3 ADC, dual payload)

SBE313. Novel biologic (EGFR-HER3 ADC, dual payload). Oncology. Phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab

SB3. Brand: SAMFENET. Biosimilar of Herceptin. Also marketed as ONTRUZANT by Organon.

Aprobado EC; Aprobado MFDS; Aprobado FDA; Aprobado TGA; Aprobado ANVISA; Aprobado TFDA; Aprobado HC (Canadá); Aprobado Medsafe; Aprobado MOHAP (EAU); Aprobado MOPH (Catar); Aprobado MHRA; Aprobado Swissmedic; Aprobado SFDA; Aprobado MoH; Aprobado KDFC (Kuwait)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab: see suppliers →

Trastuzumab deruxtecan

SB38. Biosimilar candidate of Enhertu. Oncology. Phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab deruxtecan: see suppliers →

Ustekinumab

SB17. Brand: PYZCHIVA, EPYZTEK. Biosimilar of Stelara.

Aprobado MFDS; Aprobado EC; Aprobado MHRA; Aprobado FDA; Aprobado HC (Canadá); Aprobado TGA; Aprobado ANVISA; Aprobado Swissmedic; Aprobado MHLW (Japón)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ustekinumab: see suppliers →

Vedolizumab

SB36. Biosimilar candidate of Entyvio. Immunology. Phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Vedolizumab: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free